Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis/Orion Comtan Enters COMT Field Without Liver Warnings

Executive Summary

Novartis will launch Comtan into the catechol-O-methyltransferase inhibitor class without warnings concerning hepatic toxicity.

You may also be interested in...



Novartis Alzheimer's Drug Exelon Captures 25% Of New Rxs In U.S.

Novartis is finding room for new Rx growth in the Alzheimer's treatment category, where Exelon has nearly doubled its share of new Rxs in the past two months.

Novartis Alzheimer's Drug Exelon Captures 25% Of New Rxs In U.S.

Novartis is finding room for new Rx growth in the Alzheimer's treatment category, where Exelon has nearly doubled its share of new Rxs in the past two months.

Roche Tasmar Relabeling Adds Patient Consent Form Citing Liver Toxicity

The relabeling of Roche's Parkinson's therapy Tasmar (tolcapone) to reflect reports of severe liver toxicity includes a consent form requiring patients to acknowledge that they are risking fatal side effects by taking the drug.

Related Content

UsernamePublicRestriction

Register

PS035053

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel